Hubungan IgG (IgG1 Dan IgG2) Dengan Stadium Dalam Penanggulangan Karsinoma Payudara
Hutagalung, Humala Nagatua
MetadataShow full item record
In breast cancer the stage (TNM) determines the treatment as well as the prognosis. The transformation of a normal cell to a malignancy can result that the tumors express the antigens (unique tumor-specific antigens and tumors associated antigens ) which permit the immunologic reaction. Serologic analysis of antibody responses (IgG and subclasses) may be much more common. The objective of the study is 1. to analyse whether there is a relationship between the stages and the shift of the concentration of IgG in the peripheral blood; 2. to analyse whether the shift of the concentration of lgG is followed by the shift of the concentration of IgG subclasses (IgGl and IgG2); 3. to analyse whether there is a correlation between the shift of IgG concentration and the shift of the subclasses concentration; 4. to analyse whether the shift can be applied clinically 57 women age 25-79 years from September 2001 untill March 2003, who were newly diagnosed with breast cancers (18 early stages, 22 locally advanced and 17 metastasic breast cancers) were examined for the association of the concentrations of the IgG,IgGl and IgG2 in the peripheral blood and the stages of the tumors. All blood were collected and allowed to clot following centrifugation of 3000 rpm at room temperature. All sample were stored at - 40 C temperature until use. For the determination of IgG and the subclasses, commercially available RID plates from the binding sites were used. 20 healthy women were taken as control. The result of the study shows the mean concentration of IgG and IgG1 between the stages and the control group are statistically different,(p< 0.005 and p< 0.05) but not with the mean concentration of IgG2. There is a strong positive correlation between the shift of the concentration of IgG and IgGl (r = 0.9) and a weak positive correlation between the shift of the mean concentration of IgG and IgG2 (r = 0.3). The Cut off point of IgG between the healthy control and the cancer patient is 12.8 mg/ml (sensitivity 75 %, specificity 79 %), the cut off point of IgGl between the operable and the non- operable is 8.21 mg/ml (sensitivity 60 %, spesificity 61 %), the cut off point of IgG2 between the operable and the non-operable is 5.5 mg/ml (sensitivity 70 % spesificity 71%). The analysis of IgG, IgG1 and IgG2 may significantly contribute to the immunodiagnosis of patient with breast cancer.